Acute myocardial infarction
Conditions
Interventions
Standard-care group (Standard treatment without Heart-protecting musk pills):None
Heart-protecting musk pills group (Adding Heart-protecting musk pills for therapy based on standard treatment):None
Sponsors
Beijing Friendship Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. All patients diagnosed with acute myocardial infarction in Capital Medical University, Beijing Friendship Hospital between November 1, 2022, and November 1, 2023, received PCI treatment within 1 week of onset and successfully opened the criminal's blood vessels recruited; 2. Aged 18-80 years inclusive; 3. Left ventricular ejection fraction (LVEF) is more than 35% confirmed by transthoracic cardiac ultrasound; 4. The subjects voluntarily undergo all examinations and follow-up assessments required by the study protocol; 5. The subjects (or legal guardians) understand the study requirements and treatment procedures and sign written informed consent before performing the tests or procedures prescribed in the protocol.
Exclusion criteria
Exclusion criteria: 1. Previous history of myocardial infarction; 2. Coronary angiography confirms a chronic complete occlusive coronary artery lesion or left main trunk lesion; 3. The subjects cannot tolerate antiplatelet therapy; 4. Significant hematopoietic abnormalities include blood plates 700 x 10^9/L and white blood cells < 3 x 10^9/L; 5. Active bleeding and obvious bleeding tendencies, such as active ulcer, recent ischemic stroke, history of hemorrhagic stroke, intracranial mass lesions, recent craniocerebral trauma, and other organs with active bleeding or bleeding tendency that is not easy to stop bleeding; 6. Associated with another organ failure, such as severe renal insufficiency (GFR < 30 ml/min•1.73 m^2) or severe hepatic impairment (AST or ALT elevation more than 3 times the upper limit of normal), combined with severe congestive heart failure (cardiac more than or equal to Grade III) and so on; 7. Have a serious disease with an expected life expectancy of fewer than 12 months, such as malignancy, advanced other diseases, etc.; 8. Pregnant women and women planning to become pregnant; 9. Acute infectious diseases; 10. Comorbid immune system disorders; 11. The subjects are allergic to or contraindicated to concomitant medications required by the study stent system or protocol (e.g., aspirin, clopidogrel, ticagrelor, statins, contrast agents, anticoagulants, stent-coated drugs, stainless steel, etc.); 12. The subjects with cognitive impairment, severe hearing, and visual impairment were unable to complete group communication, and the subjects who refuse review; 13. The subjects who are participating in a clinical trial of another drug or device that has not met the primary endpoint, or plan to participate in a clinical trial of another drug or device within 12 months of surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of infarct area to left ventricular mass ratio;Change of intramyocardial hemorrhage (IMH);Change of infarct size (IS);Change of edema myocardial area; | — |
Secondary
| Measure | Time frame |
|---|---|
| The change of microvascular occlusion area (MVO);The change of LVEF,infarct area and surviving myocardial area 1 year after PCI evaluated CMR;Major Adverse Cardiovascular Events, MACEs;Major Adverse Cardiovascular Events, MACEs;MACEs of every event;The grade of cardiac function NAHY;The angina grading of the Canadian Society of Cardiology;The changes in the parameters of the Quality of Life Scale;The occurrence of adverse reactions; | — |
Countries
China
Contacts
Public ContactHuang Rongchong
Beijing Friendship Hospital, Capital Medical University
Outcome results
None listed